scholarly journals Molecular evolution of peptides by yeast surface display technology

MedChemComm ◽  
2019 ◽  
Vol 10 (9) ◽  
pp. 1569-1580 ◽  
Author(s):  
Sara Linciano ◽  
Stefano Pluda ◽  
Arianna Bacchin ◽  
Alessandro Angelini
Keyword(s):  
Molecular Evolution ◽  
Detailed Analysis ◽  
Surface Display ◽  
Yeast Surface Display ◽  
Display Technology ◽  
Yeast Surface

This review provides a detailed analysis of the diverse genetically encoded peptides that have been evolved by using yeast surface display technology.

scholarly journals A Decade of Yeast Surface Display Technology: Where Are We Now?

2008 ◽  
Vol 11 (2) ◽  
pp. 127-134 ◽  
Author(s):  
Eric Shusta ◽  
Lauren Pepper ◽  
Yong Cho ◽  
Eric Boder
Keyword(s):  
Surface Display ◽  
Yeast Surface Display ◽  
Display Technology ◽  
Yeast Surface

Functional expression, production, and biochemical characterization of a laccase using yeast surface display technology

2016 ◽  
Vol 120 (12) ◽  
pp. 1609-1622 ◽  
Author(s):  
Brandt Bertrand ◽  
María R. Trejo-Hernández ◽  
Daniel Morales-Guzmán ◽  
Luis Caspeta ◽  
Ramón Suárez Rodríguez ◽  
...  
Keyword(s):  
Biochemical Characterization ◽  
Surface Display ◽  
Functional Expression ◽  
Yeast Surface Display ◽  
Display Technology ◽  
Yeast Surface

scholarly journals Converting a broad matrix metalloproteinase family inhibitor into a specific inhibitor of MMP-9 and MMP-14

2017 ◽  
Author(s):  
Jason Shirian ◽  
Valeria Arkadash ◽  
Itay Cohen ◽  
Tamila Sapir ◽  
Evette S. Radisky ◽  
...  
Keyword(s):  
Matrix Metalloproteinase ◽  
Surface Display ◽  
Specific Inhibitor ◽  
Computational Design ◽  
Yeast Surface Display ◽  
Physiological Conditions ◽  
Mmp Inhibitor ◽  
Single Target ◽  
Display Technology ◽  
Yeast Surface

AbstractMMP-14 and MMP-9 are two well established cancer targets for which no specific clinically relevant inhibitor is available. Using a powerful combination of computational design and yeast surface display technology, we engineered such an inhibitor starting from a non-specific MMP inhibitor, N-TIMP2. The engineered purified N-TIMP2 variants showed enhanced specificity towards MMP-14 and MMP-9 relative to a panel of off-target MMPs. MMP-specific N-TIMP2 sequence signatures were obtained that could be understood from the structural perspective of MMP/N-TIMP2 interactions. Our MMP-9 inhibitor exhibited 1000-fold preference for MMP-9 vs. MMP-14, which is likely to translate into significant differences under physiological conditions. Our results provide new insights regarding evolution of promiscuous proteins and optimization strategies for design of inhibitors with single-target specificities.

scholarly journals Selection of novel human scFvs against cancer antigen IL1RAP by phage and yeast surface display technology

2020 ◽  
Vol 34 (1) ◽  
pp. 287-293
Author(s):  
Shixin Duan ◽  
Yanrong Jia ◽  
Debao Xie ◽  
Shenglin Xiao ◽  
Cheng Zhou ◽  
...  
Keyword(s):  
Surface Display ◽  
Yeast Surface Display ◽  
Cancer Antigen ◽  
Display Technology ◽  
Yeast Surface ◽  
Selection Of

scholarly journals Development and Characterization of Two Types of Surface Displayed Levansucrases for Levan Biosynthesis

Catalysts ◽  
2021 ◽  
Vol 11 (7) ◽  
pp. 757
Author(s):  
Huiyi Shang ◽  
Danni Yang ◽  
Dairong Qiao ◽  
Hui Xu ◽  
Yi Cao
Keyword(s):  
Saccharomyces Cerevisiae ◽  
Molecular Weight ◽  
Large Scale ◽  
Surface Display ◽  
Yeast Surface Display ◽  
Fusion Partner ◽  
Whole Cell ◽  
Food Industries ◽  
Yeast Surface ◽  
The Stability

Levan has wide applications in chemical, cosmetic, pharmaceutical and food industries. The free levansucrase is usually used in the biosynthesis of levan, but the poor reusability and low stability of free levansucrase have limited its large-scale use. To address this problem, the surface-displayed levansucrase in Saccharomyces cerevisiae were generated and evaluated in this study. The levansucrase from Zymomonas mobilis was displayed on the cell surface of Saccharomyces cerevisiae EBY100 using a various yeast surface display platform. The N-terminal fusion partner is based on a-agglutinin, and the C-terminal one is Flo1p. The yield of levan produced by these two whole-cell biocatalysts reaches 26 g/L and 34 g/L in 24 h, respectively. Meanwhile, the stability of the surface-displayed levansucrases is significantly enhanced. After six reuses, these two biocatalysts retained over 50% and 60% of their initial activities, respectively. Furthermore, the molecular weight and polydispersity test of the products suggested that the whole-cell biocatalyst of levansucrase displayed by Flo1p has more potentials in the production of levan with low molecular weight which is critical in certain applications. In conclusion, our method not only enable the possibility to reuse the enzyme, but also improves the stability of the enzyme.

Sign in / Sign up

Export Citation Format

Share Document